ANAC -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist7 months ago

    Dupixent Could Substantially Drive Regeneron’s Growth

    In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

  • Market Realist11 months ago

    New Product Launches May Boost Valeant’s Dermatology Revenue

    New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after ...

  • We're sorry this is all we were able to find about this topic.